Significant Ownership of Avidity Partners Management LP
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Avidity Partners Management LP focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- By: Avidity Partners Management (GP) LLC, its general partner, /s/ Michael Gregory - Michael Gregory, Managing Member
- Manager location
- Dallas, TX
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Avidity Partners Management LP and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from Avidity Partners Management LP
Significant Ownership of Avidity Partners Management LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| IMUX | Immunic, Inc. | Common Stock, $0.0001 par value | 9.9% | $15,493,835 | +$10,277,489 | 13,958,410 | +197% | Avidity Partners Management LP | 17 Feb 2026 |
| SCYX | Scynexis, Inc. | Common Stock, par value $0.001 per share | 9.9% | $2,921,533 | -$59,527 | 4,426,565 | -2% | Avidity Partners Management LP | 31 Dec 2025 |
| CNTX | Context Therapeutics Inc. | Common Stock, par value $0.001 per share | 8.7% | $21,753,357 | -$2,352,163 | 8,302,808 | -9.8% | Avidity Partners Management LP | 31 Mar 2026 |
| SYRS | Syros Pharmaceuticals, Inc. | Common Stock, $0.001 par value | 7.6% | $61,441 | 2,048,020 | Avidity Partners Management LP | 31 Dec 2024 | ||
| KZR | Kezar Life Sciences, Inc. | Common Stock, par value $0.001 per share | 6.9% | $397,054 | 502,600 | Avidity Partners Management LP | 31 Dec 2024 | ||
| CATX | Perspective Therapeutics, Inc. | Common Stock, $0.001 par value | 5.3% | $29,523,995 | +$15,659,798 | 6,049,999 | +113% | Avidity Partners Management LP | 20 Feb 2026 |
| DNTH | Dianthus Therapeutics, Inc. | Common Stock, $0.001 par value | 4.9% | $70,995,168 | -$43,010,234 | 2,104,184 | -38% | Avidity Partners Management LP | 17 Nov 2025 |
| KZR | Kezar Life Sciences, Inc. | Common Stock, par value $0.001 per share | 0% | $0 | 0 | Avidity Partners Management LP | 30 Sep 2025 |
Schedules 13D/G Reported by Avidity Partners Management LP:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.